BVAXF
Price
$0.04
Change
-$0.00 (-0.00%)
Updated
Apr 2 closing price
Capitalization
8.25M
CSBR
Price
$8.17
Change
-$0.68 (-7.68%)
Updated
Apr 3 closing price
Capitalization
112.97M
104 days until earnings call
Ad is loading...

BVAXF vs CSBR

Header iconBVAXF vs CSBR Comparison
Open Charts BVAXF vs CSBRBanner chart's image
BioVaxys Technology
Price$0.04
Change-$0.00 (-0.00%)
Volume$6.5K
Capitalization8.25M
Champions Oncology
Price$8.17
Change-$0.68 (-7.68%)
Volume$91.13K
Capitalization112.97M
BVAXF vs CSBR Comparison Chart
Loading...
BVAXF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CSBR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BVAXF vs. CSBR commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BVAXF is a Hold and CSBR is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (BVAXF: $0.04 vs. CSBR: $8.17)
Brand notoriety: BVAXF and CSBR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BVAXF: 24% vs. CSBR: 206%
Market capitalization -- BVAXF: $8.25M vs. CSBR: $112.97M
BVAXF [@Biotechnology] is valued at $8.25M. CSBR’s [@Biotechnology] market capitalization is $112.97M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BVAXF’s FA Score shows that 0 FA rating(s) are green whileCSBR’s FA Score has 0 green FA rating(s).

  • BVAXF’s FA Score: 0 green, 5 red.
  • CSBR’s FA Score: 0 green, 5 red.
According to our system of comparison, both BVAXF and CSBR are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BVAXF’s TA Score shows that 0 TA indicator(s) are bullish while CSBR’s TA Score has 4 bullish TA indicator(s).

  • BVAXF’s TA Score: 0 bullish, 2 bearish.
  • CSBR’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, both BVAXF and CSBR are a bad buy in the short-term.

Price Growth

BVAXF (@Biotechnology) experienced а -2.01% price change this week, while CSBR (@Biotechnology) price change was -14.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.91%. For the same industry, the average monthly price growth was -11.19%, and the average quarterly price growth was -14.86%.

Reported Earning Dates

CSBR is expected to report earnings on Jul 17, 2025.

Industries' Descriptions

@Biotechnology (-8.91% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CSBR($113M) has a higher market cap than BVAXF($8.25M). CSBR YTD gains are higher at: -4.667 vs. BVAXF (-15.366). CSBR has higher annual earnings (EBITDA): 1.43M vs. BVAXF (-5.67M). CSBR has higher revenues than BVAXF: CSBR (53.6M) vs BVAXF (0).
BVAXFCSBRBVAXF / CSBR
Capitalization8.25M113M7%
EBITDA-5.67M1.43M-395%
Gain YTD-15.366-4.667329%
P/E RatioN/A19.67-
Revenue053.6M-
Total CashN/A2.75M-
Total DebtN/A6.78M-
FUNDAMENTALS RATINGS
BVAXF vs CSBR: Fundamental Ratings
BVAXF
CSBR
OUTLOOK RATING
1..100
7460
VALUATION
overvalued / fair valued / undervalued
1..100
46
Fair valued
84
Overvalued
PROFIT vs RISK RATING
1..100
9969
SMR RATING
1..100
10099
PRICE GROWTH RATING
1..100
6339
P/E GROWTH RATING
1..100
10055
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BVAXF's Valuation (46) in the null industry is somewhat better than the same rating for CSBR (84) in the Biotechnology industry. This means that BVAXF’s stock grew somewhat faster than CSBR’s over the last 12 months.

CSBR's Profit vs Risk Rating (69) in the Biotechnology industry is in the same range as BVAXF (99) in the null industry. This means that CSBR’s stock grew similarly to BVAXF’s over the last 12 months.

CSBR's SMR Rating (99) in the Biotechnology industry is in the same range as BVAXF (100) in the null industry. This means that CSBR’s stock grew similarly to BVAXF’s over the last 12 months.

CSBR's Price Growth Rating (39) in the Biotechnology industry is in the same range as BVAXF (63) in the null industry. This means that CSBR’s stock grew similarly to BVAXF’s over the last 12 months.

CSBR's P/E Growth Rating (55) in the Biotechnology industry is somewhat better than the same rating for BVAXF (100) in the null industry. This means that CSBR’s stock grew somewhat faster than BVAXF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BVAXFCSBR
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
88%
Stochastic
ODDS (%)
N/A
Bullish Trend 2 days ago
78%
Momentum
ODDS (%)
Bearish Trend about 1 month ago
90%
Bearish Trend 2 days ago
85%
MACD
ODDS (%)
Bearish Trend about 1 month ago
90%
Bearish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bearish Trend about 1 month ago
90%
Bearish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bearish Trend about 1 month ago
90%
Bearish Trend 2 days ago
78%
Advances
ODDS (%)
N/A
Bullish Trend 18 days ago
75%
Declines
ODDS (%)
N/A
Bearish Trend 3 days ago
78%
BollingerBands
ODDS (%)
N/A
Bullish Trend 2 days ago
85%
Aroon
ODDS (%)
N/A
Bearish Trend 2 days ago
74%
View a ticker or compare two or three
Ad is loading...
BVAXF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CSBR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FUNCX26.68N/A
N/A
Pioneer Fundamental Growth C
KTCSX36.55N/A
N/A
DWS Science and Technology S
AUICX31.37N/A
N/A
AB Equity Income C
HRISX14.57N/A
N/A
Harbor International Small Cap Admin
CSMAX13.78N/A
N/A
Calvert Global Small-Cap Equity A

BVAXF and

Correlation & Price change

A.I.dvisor tells us that BVAXF and GSGTF have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BVAXF and GSGTF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BVAXF
1D Price
Change %
BVAXF100%
+1.02%
GSGTF - BVAXF
29%
Poorly correlated
N/A
THTX - BVAXF
24%
Poorly correlated
+5.00%
EDSA - BVAXF
21%
Poorly correlated
+5.60%
CSBR - BVAXF
21%
Poorly correlated
+2.79%
SEPSF - BVAXF
20%
Poorly correlated
N/A
More